Woodline Partners’s Larimar Therapeutics LRMR Stock Holding History
Bought
Maintained
Sold
Other funds holding LRMR
Woodline Partners's LRMR Position: Q3 2026 in Review
Woodline Partners held its Larimar Therapeutics (LRMR) position steady in Q3 2026 at 1,400,850 shares worth $4.48M. The position accounts for 0.01% of the portfolio, ranked #740.
Woodline Partners first reported a position in LRMR in Q3 2022 and has held it in 17 quarters since. The position peaked at $9.01M in Q2 2024. 147 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.
- Woodline Partners held 1,400,850 shares of Larimar Therapeutics worth $4.48M as of Q3 2026.
- Woodline Partners left its Larimar Therapeutics share count unchanged in Q3 2026.
- Larimar Therapeutics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #740 holding.
- Woodline Partners first reported a position in Larimar Therapeutics in Q3 2022 and has held it in 17 quarters since.
- Woodline Partners's Larimar Therapeutics position peaked at $9.01M in Q2 2024.
- 147 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.